Description
Nova Mentis Life Science Corp., through its subsidiaries, focuses on developing medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder. It is also involved in the research and development of psychedelic medicines for metabolic indications, such as obesity and diabetes. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
